GSK Announces $0.4206 Quarterly Dividend with 4.53% Yield

GSK has declared a quarterly dividend of $0.4206 per share, offering a 4.53% yield. Analysts project a moderate upside for the stock, with a price target range of $34.09 to $45.00, and GuruFocus estimates suggest a significant upside based on the GF Value metric. The average brokerage recommendation is 2.9, indicating a "Hold" status.

GSK plc (GSK) has declared a quarterly dividend of $0.4206 per share, offering a 4.53% yield. This dividend announcement comes on the heels of the company's robust interim results for the second quarter of 2025, where it reported £16 billion in revenue, in line with analyst forecasts, and statutory earnings per share of £0.35, beating expectations [1].

Analysts have updated their forecasts in light of these results. They now expect £32.0 billion in revenues and a 53% increase in earnings per share to £1.30 in 2025. The consensus price target remains at £16.52, with a wide range of estimates suggesting a diverse view on possible outcomes for the business. Analysts expect GSK's growth to accelerate, with a forecast 2.1% annualised growth to the end of 2025 [1].

According to MarketBeat, based on 4 analysts' ratings, GSK has a consensus rating of "Hold." The average price target is GBX 1,683.33, with the highest target at GBX 2,000 and the lowest at GBX 1,450. The average price target represents a forecasted upside of 20.41% from the current price of GBX 1,398 [2].

GuruFocus estimates suggest a significant upside based on the GF Value metric. The average brokerage recommendation is 2.9, indicating a "Hold" status [3].

In summary, GSK's quarterly dividend and analyst forecasts provide a mixed outlook. While the dividend offers a moderate yield, the price target range suggests a potential for significant upside. Investors should carefully consider these factors and monitor GSK's performance to make informed investment decisions.

References:
[1] https://www.ainvest.com/news/gsk-plc-interim-report-revenue-line-forecasts-eps-beats-expectations-2508/
[2] https://www.marketbeat.com/stocks/LON/GSK/forecast/
[3] https://www.ainvest.com/news/newmont-corp-divests-orosur-mining-stake-analysts-17-54-upside-2508/